In last trading session, Viking Therapeutics, Inc. (NASDAQ:VKTX) saw 1,643,373 shares changing hands with its beta currently measuring 2.07. Company’s recent per share price level of $7.76 trading at $0.3 or 4.44% at ring of the bell on the day assigns it a market valuation of $563.35 Million. That closing price of VKTX’s stock is at a discount of -14.3% from its 52-week high price of $8.87 and is indicating a premium of 57.99% from its 52-week low price of $3.26. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.52 Million shares which gives us an average trading volume of 1.64 Million if we extend that period to 3-months.
For Viking Therapeutics, Inc. (VKTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.6. Splitting up the data highlights that, out of 14 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 14 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.14 in the current quarter.
Viking Therapeutics, Inc. (NASDAQ:VKTX) trade information
Upright in the green today for gaining 4.44%, in the last five days VKTX remained trading in the green while hitting it’s week-highest on Tuesday, Jun 23 when the stock touched $8.36-7 price level, adding 7.15% to its value on the day. Viking Therapeutics, Inc.’s shares saw a change of -3.24% in year-to-date performance and have moved 3.19% in past 5-day. Viking Therapeutics, Inc. (NASDAQ:VKTX) showed a performance of -2.39% in past 30-days. Number of shares sold short was 10.98 Million shares which calculate 6.7 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $18.38 to the stock, which implies a rise of 136.86% to its current value. Analysts have been projecting $9 as a low price target for the stock while placing it at a high target of $40. It follows that stock’s current price would jump +415.46% in reaching the projected high whereas dropping to the targeted low would mean a loss of 15.98% for stock’s current value.
Viking Therapeutics, Inc. (VKTX) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 32.4% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 6.5% while estimates for its earnings growth in next 5 years are of 40%
Viking Therapeutics, Inc. (NASDAQ:VKTX)’s Major holders
Insiders are in possession of 10.98% of company’s total shares while institution are holding 56.67% percent of that, with stock having share float percentage of 63.66%. Investors also watch the number of corporate investors in a company very closely, which is 202 institutions for Viking Therapeutics, Inc. that are currently holding shares of the company. ArrowMark Colorado Holdings LLC is the top institutional holder at VKTX for having 8.82 Million shares of worth $41.3 Million. And as of March 30, 2020, it was holding 12.16% of the company’s outstanding shares.
The second largest institutional holder is Blackrock Inc., which was holding about 4.75 Million shares on March 30, 2020. The number of shares represents firm’s hold over 6.54% of outstanding shares, having a total worth of $22.22 Million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Explorer Fund, Inc. are the top two Mutual Funds which own company’s shares. As of March 30, 2020, the former fund manager was holding 2350841 shares of worth $11Million or 3.24% of the total outstanding shares. The later fund manager was in possession of 2.01 Million shares on January 30, 2020, making its stake of worth around $12.62 Million in the company or a holder of 2.77% of company’s stock.